Top

Published in:

01-12-2021 | Wound Infection | Research article

The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates

Authors: Antonella Vecchiato, Simone Mocellin, Paolo Del Fiore, Giulio Tosti, Paolo A. Ascierto, Maria Teresa Corradin, Vincenzo De Giorgi, Giuseppe Giudice, Paola Queirolo, Caterina Ferreli, Marcella Occelli, Monica Giordano, Giusto Trevisan, Luigi Mascheroni, Alessandro Testori, Romina Spina, Alessandra Buja, Francesco Cavallin, Corrado Caracò, Antonio Sommariva, Carlo Riccardo Rossi, on behalf of the Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup (IMI)

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Reproducible, high-quality surgery is a key point in the management of cancer patients. Quality indicators for surgical treatment of melanoma has been presented with benchmarks but data on morbidity are still limited. This study presents the quality indicators on morbidity after surgical treatment for non-metastatic skin melanoma in an Italian registry.

Methods

Data were extracted from the Central National Melanoma Registry (CNMR) promoted by the Italian Melanoma Intergroup (IMI). All surgical procedures (WE, SNLB or LFND) for non-metastatic skin melanoma between January 2011 and February 2017 were evaluated for inclusion in the study. Only centers with adequate completeness of information (> 80%) were included in the study. Short-term complications (wound infection, dehiscence, skin graft failure and seroma) were investigated.

Results

Wound infection rate was 1.1% (0.4 to 2.7%) in WE, 1.3% (0.7 to 2.5%) in SLNB and 4.1% (2.1 to 8.0%) in LFND. Wound dehiscence rate was 2.0% (0.8 to 5.1%) in WE, 0.9% (0.2 to 3.0%) in SLNB and 2.8% (0.9 to 8.6%) in LFND. Seroma rate was 4.2% (1.5 to 11.1%) in SLNB and 15.1% (4.6 to 39.9%) in LFND. Unreliable information was found on skin graft failure.

Conclusions

Our findings contribute to available literature in setting up the recommended standards for melanoma centers, thus improving the quality of surgery offered to patients. A consensus on the core issues around surgical morbidity is needed to provide practical guidance on morbidity prevention and management.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Ross MI, Gershenwald JE. Evidence-based treatment of early stage melanoma. J Surg Oncol. 2011;104:341–53. https://doi.org/10.1002/jso.21962.CrossRefPubMed

Swetter SM, Tsao H, Bichakjian CK, Curiel-Lewandrowski C, Elder DE, Gershenwald JE, Guild V, Grant-Kels JM, Halpern AC, Johnson TM, Sober AJ, Thompson JA, Wisco OJ, Wyatt S, Hu S, Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208–50. https://doi.org/10.1016/j.jaad.2018.08.055.CrossRefPubMed

Sullivan R, Alatise OI, Anderson BO, et al. Global cancer surgery: delivering safe, affordable, and timely cancer surgery. Lancet Oncol. 2015;16:1193–224. https://doi.org/10.1016/S1470-2045(15)00223-5.CrossRefPubMed

Merkow RP, Bilimoria KY, Ko CY. Surgical quality measurement: an evolving science. JAMA Surg. 2013;148:586–7. https://doi.org/10.1001/jamasurg.2013.128.CrossRefPubMed

Pasquali S, Sommariva A, Spillane AJ, Bilimoria KY, Rossi CR. Measuring the quality of melanoma surgery - highlighting issues with standardization and quality assurance of care in surgical oncology. Eur J Surg Oncol. 2017;43:561–71. https://doi.org/10.1016/j.ejso.2016.06.397.CrossRefPubMed

Pasquali S, Spillane A. Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy. Cancer Treat Rev. 2014;40:893–9. https://doi.org/10.1016/j.ctrv.2014.06.008.CrossRefPubMed

Bilimoria KY. Moving beyond guidelines to ensure high-quality cancer care in the United States. J Oncol Pract. 2012;8:e67–8. https://doi.org/10.1200/JOP.2012.000686.CrossRefPubMedPubMedCentral

Rossi CR, Mozzillo N, Maurichi A, Pasquali S, Macripò G, Borgognoni L, Solari N, Piazzalunga D, Mascheroni L, Giudice G, Mocellin S, Patuzzo R, Caracò C, Ribero S, Marone U, Santinami M. Number of excised lymph nodes as a quality assurance measure for lymphadenectomy in melanoma. JAMA Surg. 2014;149:700–6. https://doi.org/10.1001/jamasurg.2013.5676.CrossRefPubMed

10.

Sommariva A, Clemente C, Rossi CR. Standardization and quality control of surgical treatment of cutaneous melanoma: looking for consensus of the Italian melanoma intergroup. Eur J Surg Oncol. 2015;41:148–56. https://doi.org/10.1016/j.ejso.2014.07.035.CrossRefPubMed

11.

U.S. Department of Health and Human Services (2010) Common terminology criteria for adverse events v4.03 (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

12.

R Core Team. R: a language and environment for statistical computing. In: R Foundation for statistical computing. Vienna; 2018. URL https://www.R-project.org/.

13.

Morton DL, Cochran AJ, Thompson JF, Elashoff R, Essner R, Glass EC, Mozzillo N, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP, Reintgen DS, Coventry BJ, Wang HJ, Multicenter Selective Lymphadenectomy Trial Group. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242(3):302–11; discussion 311-3. https://doi.org/10.1097/01.sla.0000181092.50141.fa.CrossRefPubMedPubMedCentral

14.

Moody JA, Ali RF, Carbone AC, Singh S, Hardwicke JT. Complications of sentinel lymph node biopsy for melanoma - a systematic review of the literature. Eur J Surg Oncol. 2017;43:270–7. https://doi.org/10.1016/j.ejso.2016.06.407.CrossRefPubMed

15.

Moody JA, Botham SJ, Dahill KE, Wallace DL, Hardwicke JT. Complications following completion lymphadenectomy versus therapeutic lymphadenectomy for melanoma - a systematic review of the literature. Eur J Surg Oncol. 2017;43:1760–7. https://doi.org/10.1016/j.ejso.2017.07.003.CrossRefPubMed

16.

Gheorghe A, Moran G, Duffy H, Roberts T, Pinkney T, Calvert M. Health utility values associated with surgical site infection: a systematic review. Value Health. 2015;18(8):1126–37.CrossRefPubMed

17.

Brusaferro S, Arnoldo L, Finzi G, Mura I, Auxilia F, Pasquarella C, Agodi A, Board; Group. Hospital Hygiene and Infection Prevention and Control in Italy: state of the art and perspectives. Ann Ig. 2018;30(5 Supple 2):1–6. https://doi.org/10.7416/ai.2018.2245.CrossRefPubMed

18.

Hernandez-Boussard T, Downey JR, McDonald K, Morton JM. Relationship between patient safety and hospital surgical volume. Health Serv Res. 2012;47(2):756–69. https://doi.org/10.1111/j.1475-6773.2011.01310.x Epub 2011 Aug 30.CrossRefPubMed

Title: The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates
Authors: Antonella Vecchiato
Simone Mocellin
Paolo Del Fiore
Giulio Tosti
Paolo A. Ascierto
Maria Teresa Corradin
Vincenzo De Giorgi
Giuseppe Giudice
Paola Queirolo
Caterina Ferreli
Marcella Occelli
Monica Giordano
Giusto Trevisan
Luigi Mascheroni
Alessandro Testori
Romina Spina
Alessandra Buja
Francesco Cavallin
Corrado Caracò
Antonio Sommariva
Carlo Riccardo Rossi
on behalf of the Clinical National Melanoma Registry Study Group at the Italian Melanoma Intergroup (IMI)
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Wound Infection
Wound Dehiscence
Seroma
Skin Graft
Melanoma
Melanoma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-020-07705-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Determinants of the access to remote specialised services provided by national sarcoma reference centres

Cardiovascular events and mortality in a population-based cohort initially diagnosed with ductal carcinoma in situ

The mediation effect of serum metabolites on the relationship between long-term smoking exposure and esophageal squamous cell carcinoma

The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma

Variation rs9929218 and risk of the colorectal Cancer and adenomas: A meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer